T he American College of Cardiology and American
Heart Association (ACC/AHA) 1 have released updated practice guidelines for the management of unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI). The new recommendations are based on relevant clinical evidence published since the previous 2000 guidelines ( Table 1 ). The complete 2002 guidelines are available on the ACC Web site. The summary article is also published in the Journal of the American College of Cardiology and Circulation. 2 These guidelines complement and overlap the previously released ACC/AHA 1999 guidelines for the Management of Patients with Acute Myocardial Infarction (reviewed in The Annals 2001;35:589-617). The purpose of this editorial is to summarize key changes in the recommendations for drug therapy, particularly those involving the use of antiplatelet and anticoagulant drugs.
Acute coronary syndromes (ACSs) include 3 clinical conditions: ST-segment elevation myocardial infarction (STEMI, previously termed Q-wave), NSTEMI (previously termed non-Q wave), and UA. 1 These conditions share a common pathophysiology characterized by atherosclerotic plaque disruption and activation of the coagulation cascade. UA and NSTEMI are closely related conditions that may present with similar symptoms, T-wave changes, and ST-segment depression. Three clinical presentations of UA are recognized: rest angina usually prolonged over 20 minutes, new-onset angina associated with marked limitation or inability to carry on physical activity, and previously di-agnosed angina that is increasing in frequency or duration. NSTEMI is distinguished by the presence of elevated markers of myocardial injury.
Aspirin and Clopidogrel
The guidelines significantly expand the role of clopidogrel in patients with UA/NSTEMI. The panel continues to recommend that aspirin be initiated immediately on presentation and continued indefinitely. For aspirin-intolerant patients, prior guidelines recommended clopidogrel or ticlopidine as suitable alternatives. The 2002 guidelines identify clopidogrel as the agent of choice due to a faster onset of action and greater safety. The CLASSICS (CLopidogrel ASpirin Stent International Cooperative Study) 2 compared the safety of clopidogrel 75 mg/d with or without a 300-mg loading dose or ticlopidine 250 mg twice daily in 1020 patients undergoing stent implantation; all patients were also taking aspirin. The primary endpoints of major bleeding, neutropenia, thrombocytopenia, or early drug discontinuation for noncardiac adverse effects occurred in 9.1% of ticlopidine patients versus 4.6% of clopidogrel patients (p = 0.005). While both clopidogrel and ticlopidine have been reported 3,4 to cause thrombotic thrombocytopenic purpura, a potentially fatal adverse effect, fewer cases have been documented with clopidogrel.
The most significant change in the guidelines related to antiplatelet therapy is the recommendation that aspirin-tolerant patients also be initiated on clopidogrel as soon as possible after admission. Combined therapy should be administered for at least 1 month and up to 9 months unless bleeding risks are high. This recommendation applies both to patients managed early by noninvasive approaches and those who will undergo percutaneous coronary intervention (PCI). These recommendations are based on evidence from the CURE (Clopidogrel in Unstable angina to pre-vent Recurrent ischemic Events) 5 and the PCI-CURE 6 trials. CURE 5 randomized 12 562 patients presenting within 24 hours with UA/NSTEMI to receive placebo or clopidogrel (loading dose 300 mg followed by 75 mg/d) in combination with aspirin. The combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke occurred in 11.4% of placebo patients and 9.3% of clopidogrel patients (RR 0.80; p < 0.001). However, the difference in the composite endpoint was due almost entirely to a reduction in MIs (RR 0.77; 95% CI 0.67 to 0.89). Clopidogrel also significantly reduced the incidence of severe (p = 0.003) or refractory (p = 0.007) in-hospital ischemia, heart failure (p = 0.028), and revascularization procedures (p = 0.03). Benefits were maintained over a treatment period averaging 9 months. Major bleeding occurred in 3.7% of clopidogreltreated patients compared with 2.7% of placebo patients (p = 0.001), but there was no difference in the incidence of life-threatening bleeds or hemorrhagic strokes. Because 77% of the patients did not undergo revascularization procedures during the initial admission, the trial provided strong evidence for combined clopidogrel-aspirin use in patients who did not undergo invasive treatment. The results should not be extrapolated to patients treated with invasive procedures.
The expanded recommendations for clopidogrel raise several important questions about the relative benefits and risks of this approach. The 2% absolute risk reduction in the CURE composite primary endpoint translates into a number needed to treat of 50 persons to prevent 1 event (primarily nonfatal MI). However, this risk reduction comes at the expense of a 1% increase in major bleeding (number needed to treat = 100 pts.). The guidelines do not address the economic impact of the expanded use of clopidogrel which, at more than $3.00 per day, is significant. A recent cost-effectiveness study 7 estimated that clopidogrel alone or in combination with aspirin for all eligible coronary pa-tients would cost $130 000 per quality-adjusted year of life. Others 8 have argued that achieving proponents' claims that clopidogrel could prevent 250 000-500 000 coronary events worldwide would cost approximately $10 -20 billion. In addition, because the CURE population represented a high-risk group primarily composed of patients with electrocardiographic evidence of ischemia or elevated cardiac markers, the results should not be extended to all patients presenting with chest pain.
Since many institutions routinely use a more aggressive approach with early angiography and revascularization, a subgroup analysis was conducted on all CURE patients undergoing PCI during the follow-up period. The PCI-CURE study 6 included 2658 patients who had received aspirin and clopidogrel or placebo for a median of 10 days before PCI. The composite 30-day endpoint of cardiovascular death, MI, or urgent target-vessel revascularization occurred in 6.4% of placebo patients and 4.5% of clopidogrel patients (RR 0.70; p = 0.03). After PCI, most patients continued open-label clopidogrel for an additional 8 months. During the follow-up period, there were significantly fewer MIs in the clopidogrel group (RR 0.71; 95% CI 0.51 to 0.99). These findings suggested that clopidogrel should be used routinely in patients undergoing PCI and probably continued for up to 9 months. However, the trial had some important limitations, including the fact that early and late PCI procedures were combined and glycoprotein (GP) IIb/IIIa inhibitor use was discouraged. Since many US hospitals utilize an aggressive approach with routine administration of GP IIb/IIIa inhibitors, the relative benefits and risks of clopidogrel in this setting remain unclear.
In patients scheduled for elective coronary artery bypass graft (CABG) surgery, the guidelines recommend stopping clopidogrel 5-7 days prior to the procedure. If patients undergo diagnostic catheterization within 24-36 hours of admission, clopidogrel may be withheld until it is determined whether CABG will not be scheduled. Clopidogrel can then be started after catheterization or, alternatively, a loading dose can be administered during the procedure if PCI is to be performed. These recommendations stem from the CURE 5 finding of a trend toward excess major bleeding in 912 patients who underwent CABG within the first 5 days of stopping clopidogrel compared with placebo (9.6% vs. 6.3%; p = 0.06). Patients discontinuing clopidogrel for >5 days had no excess bleeding. The recommendation to withhold clopidogrel 5-7 days prior to CABG surgery may present unique challenges, especially in the US, where early surgical revascularization is common. However, if surgery is performed before 5 days have elapsed, the 3.3% increase in the absolute risk of major bleeding is a serious concern. The potential impact of such delays on lengths of hospitalization for surgery patients requires further study.
Glycoprotein IIb/IIIa Inhibitors
The new guidelines include several updated recommendations for the use of GP IIb/IIIa inhibitors. Similar to the previous guidelines, eptifibatide or tirofiban is recom- mended for patients with ongoing ischemia, elevated troponin concentrations, or other high-risk factors for whom a noninvasive strategy is planned. Conversely, it is recommended that abciximab not be used in patients receiving noninvasive treatment. This recommendation is based on the GUSTO (Global Use of Strategies To Open occluded coronary arteries) IV-ACS trial, 9 which included 7800 patients with UA/NSTEMI for whom early revascularization was not planned. In this trial, abciximab treatment for 24-48 hours failed to reduce the 30-day combined endpoint of death/MI; in fact, a nonsignificant increase was observed. A subsequent meta-analysis 10 combined the results of GUSTO IV-ACS and 5 additional trials evaluating GP IIb/IIIa inhibitors in patients not scheduled for revascularization. A small reduction in the odds of death/MI was seen in the treatment arm (OR 0.91; 95% CI 0.84 to 0.98; p = 0.015). Neither death nor MI was significantly reduced. In the subgroup of 38% of patients who underwent unplanned revascularizations, the odds of death/MI were lower (OR 0.89; 95% CI 0.80 to 0.98) compared with patients not undergoing revascularization (OR 0.95; 95% CI 0.86 to 1.05). Major bleeding was increased with GP IIb/IIIa inhibitor therapy compared with placebo (2.4% vs. 1.4%; p < 0.0001). The findings of these studies show that GP IIb/IIIa inhibitors provide significant benefit in patients undergoing PCI, as well as in high-risk patients who require unplanned revascularizations. In contrast, the benefit of GP IIb/IIIa inhibitors in low-risk patients remains unclear.
The new guidelines reflect our evolving understanding of the role of GP IIb/IIIa inhibitors in ACS. Few comparative drug data are available, and the relative benefits and risks of combination regimens with aspirin, clopidogrel, and lowmolecular-weight heparins (LMWHs) remain unclear. One hypothesis 11 for the unexpected trend of worsening MI/death in GUSTO -IV ACS is that prolonged abciximab infusions may not sustain adequate levels of platelet inhibition. Sixmonth results from TARGET (do Tirofiban And RheoPro Give similar Efficacy outcomes Trial) 12 showed that, in contrast to the 30-day superiority of abciximab over tirofiban, 6-month event rates were similar in patients undergoing coronary stenting. Trial investigators hypothesized that the tirofiban loading dose may have been insufficient to achieve adequate initial platelet inhibition. Given the substantial cost differential between tirofiban or eptifibatide and abciximab, the implications are significant. The impact on patient outcomes of various dosage regimens, the timing of drug administration relative to invasive procedures, and the influence of adjunct agents require further investigation.
Unfractionated and LMWHs
For anticoagulation, the guidelines recommend either subcutaneous LMWH or intravenous unfractionated heparin in addition to antiplatelet therapy with aspirin and/or clopidogrel. The LMWH enoxaparin is preferred unless CABG is planned within 24 hours. The guidelines note that LMWHs should not be considered interchangeable and specifically recommend enoxaparin as the drug of choice. This recommendation is based on data from a prospectively planned meta-analysis 13 of 2 randomized trials that demonstrated superior outcomes with enoxaparin compared with unfractionated heparin. In contrast, trials 14,15 comparing dalteparin or nadroparin with unfractionated heparin have shown unfavorable to neutral results. In a direct comparative trial, 16 enoxaparin was shown to result in significant reductions in recurrent UA and 30-day revascularizations compared with tinzaparin.
The new guidelines support the use of LMWH in patients undergoing catheterization and possible PCI based on the findings of 2 studies. Collet et al. 17 studied 451 consecutive patients with UA/NSTEMI who had received subcutaneous enoxaparin 1 mg/kg every 12 hours. Among these patients, 293 (65%) underwent coronary angiography within 8 hours of the morning LMWH dose; this was followed by immediate PCI in 132 patients. No additional doses of LMWH or unfractionated heparin were given and coagulation tests were not monitored for dosage adjustments. The mean anti-factor Xa activity at the time of catheterization was >0.5 IU/mL in 97.6% of patients, with most patients near 1.0 IU/mL. No abrupt closures or urgent revascularizations occurred. The 30-day death/MI rates were 3.0% in the PCI group, 10.8% in patients not undergoing catheterization, and 6.2% in the whole population. The 30-day major bleeding rates were 0.8% in the PCI group and 1.3% in patients without catheterization. The NICE 1 (National Investigators Collaborating on Enoxaparin) trial 18 evaluated intravenous enoxaparin 1 mg/kg in patients undergoing PCI. In this observational study, the rates of both major and minor bleeding were comparable to rates with unfractionated heparin in historical controls. These trials support the safety of enoxaparin in PCI patients, but were limited in that combined use with GP IIb/IIIa inhibitors was not evaluated.
Combined Therapy with LMWH and GP IIb/IIIa Inhibitors
The new guidelines support the combined use of LMWHs and GP IIb/IIIa inhibitors in patients with ACSs, including those undergoing PCI. Observational data from the NICE 4 trial 18 demonstrated the safety of a reduced dose of enoxaparin (0.75 mg/kg) combined with standarddose abciximab in patients undergoing PCI. Non-CABG-related bleeding events were infrequent and not increased by the addition of abciximab. The incidence of thrombocytopenia was increased compared with that in the parallel NICE last LMWH dose, no additional heparin was given. If >8 hours had elapsed, an additional intravenous bolus dose of enoxaparin 0.3 mg/kg was administered. The primary endpoint of non-CABG-related major bleeding during hospitalization for the 3 GP IIb/IIIa inhibitors ranged from 0.7% to 3.2%, which was comparable to a 2% rate from prior GP IIb/IIIa inhibitor studies used for historical comparison. Of note, a 30% decrease in platelet counts occurred in 9.4% of abciximab patients compared with 3.8% and 4.7% of tirofiban and eptifibatide patients, respectively. Clinical outcomes were similar to those from prior PCI trials.
Preliminary evidence from small randomized trials of ACS patients, including those undergoing PCI, supports the safety of GP IIb/IIIa inhibitors combined with either dalteparin 20 or enoxaparin. 21 The ACUTE II (Antithrombotic Combination Using Tirofiban and Enoxaparin) study 21 included 525 patients with ACSs. PCI was permitted after 24 hours and 8 hours after the last enoxaparin dose. The study found similar rates of major and minor bleeding and a trend toward fewer adverse events with enoxaparin compared with unfractionated heparin. Additional evidence should be gained from 2 large ongoing investigations. The A-to-Z trial 22 is an international, multicenter, randomized study comparing enoxaparin or unfractionated heparin combined with tirofiban and aspirin in high-risk NSTEMI patients. The SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization and GP IIb/IIIa Inhibitors) trial 23 is expected to enroll 8000 patients in a randomized format comparing enoxaparin and unfractionated heparin in high-risk ACS patients treated with an early invasive strategy.
Discharge Therapy
Extensive recommendations for hospital discharge and postdischarge care are also provided in the ACC/AHA guidelines, including combined aspirin and clopidogrel therapy up to 9 months, β-blockers, lipid-lowering agents, and angiotensin-converting enzyme inhibitors in patients with left-ventricular dysfunction, heart failure, hypertension, or diabetes. For patients whose low-density lipoprotein cholesterol is >100 mg/dL, the panel recommends early initiation of statins within 24 -96 hours of admission. The recommendation is derived from the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) study, 24 which demonstrated reductions in severe recurrent ischemia with early atorvastatin therapy. For patients whose high-density lipoprotein cholesterol is <40 mg/dL, there is an additional recommendation to add either gemfibrozil or niacin.
Summary
All practice guidelines are limited by the continual release of new study findings, which may impact recommendations. Nonetheless, the 2002 ACC/AHA guidelines provide comprehensive evidence-based recommendations for the management of UA/NSTEMI. Together with the previ-ous ACC/AHA guidelines for STEMI, these practice guidelines are a valuable tool for practitioners involved in the management of patients with ACS. However, practice guidelines are intended to aid, but not replace, clinical judgment. There are many opportunities for pharmacists to play an active role in the management of patients with ACS, including institution-specific critical pathways and protocol development, formulary decisions, cost-effectiveness evaluations for various treatment strategies, benefit-risk analyses for individual patients, and the dissemination of new clinical trial data.
